OverviewSuggest Edit

Karo Pharma is a healthcare company, which develops and markets products for pharmacies and the health care sectors. The Company's development projects are focused on nuclear receptors as target proteins for the development of pharmaceuticals. Its products include medical compression socks, nutritional products, ergonomic products for people with disabilities, and medicine storage products. The Company also offers medicines for the treatment of sore throats, vaginal dryness, pains, etc. Its products under development include nuclear receptor RORgamma based products for the treatment of autoimmune diseases, compounds to treat multiple sclerosis and cancer, and a common cold spray.

HQStockholm, SE

Latest Updates

Employees (est.) (Sept 2020)193
Share Price (Sept 2020)KR69.9
Cybersecurity ratingBMore

Key People/Management at Karo Pharma

Christoffer Lorenzen

Christoffer Lorenzen

Chief Executive Officer
Jon Johnsson

Jon Johnsson

Chief Financial Officer
Magnus Nylén

Magnus Nylén

Chief Sales Officer
Carl Lindgren

Carl Lindgren

Vice President Business Development
Jonathan Kimber

Jonathan Kimber

VP Operations
Sofia Pedersen

Sofia Pedersen

VP Scientific Affairs
Show more

Karo Pharma Office Locations

Karo Pharma has an office in Stockholm
Stockholm, SE (HQ)
Klara Norra kyrkogata 33
Show all (2)

Karo Pharma Financials and Metrics

Karo Pharma Revenue

Market capitalization (25-Sept-2020)


Closing stock price (25-Sept-2020)

Karo Pharma's current market capitalization is kr15.6 b.
Show all financial metrics

Karo Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Karo Pharma Online and Social Media Presence

Embed Graph

Karo Pharma News and Updates

Karo Pharma divests Hydrokortison Trimb to Evolan Pharma

As previously communicated, Karo Pharma Aktiebolag (“Karo Pharma”) voluntarily and within a certain time undertook to divest Hydrokortison Trimb and all intellectual property rights and assets relating thereto, including necessary licenses and permits as well as existing stock, to an external buyer …

Karo Pharma buys Swedish consumer healthcare firm Trimb

Karo Pharma AB has acquired Trimb, a Swedish consumer healthcare company, for about $366 million. The deal is expected to close before the end of the year. Trimb was backed by Avista Capital Partners.

Avista Capital Partners To Sell Trimb To Karo Pharma

NEW YORK and STOCKHOLM, June 25, 2019 /PRNewswire/ -- Avista Capital Partners ("Avista"), a leading private equity firm focused on growth-oriented healthcare businesses, today announced that Karo Pharma AB (publ) (the "Company" or "Karo Pharma"), a specialty pharma company, has acquired...

Karo Pharma publishes the 2018 annual report

Today, on 9 April 2019, Karo Pharma is publishing its annual report for 2018 on the company’s website, www.karopharma.com (http://%20www.karopharma.com).read more

Karo Pharma Blogs

Karo Pharma postpones the Annual General Meeting to 25 May, 2020

The board of directors of Karo Pharma Aktiebolag (”Karo Pharma”) has resolved to postpone the Annual General Meeting to 25 May, 2020. The previously communicated date for the meeting was 29 April 2020. The delay is due to the increased concern of the spread of COVID-19 with the related safety of the…

Karo Pharma completes the acquisition of product portfolio from LEO Pharma

Karo Pharma Aktiebolag (“Karo Pharma”) today announces that the acquisition of the intimate care and dermatology product portfolio from LEO Pharma for 90 MEUR, which was signed and announced by Karo Pharma on 23 December 2019 and approved by relevant competition authorities on 20 February 2020, has …

Year-end report 2019

OCTOBER – DECEMBER · Net sales amounted to MSEK 649.3 (463.3). This corresponds to an increase of 40% for the period. The organic growth during the fourth quarter was -4 %, currency impact 2 % and 42 % refers to the acquisition of Trimb. · Adjusted EBITDA* amounted to MSEK 151.4 (165.4) excluding no…

Termination of Karo agreement with Pfizer

Karo Pharma AB (“Karo”) has been informed by Pfizer Inc. (“Pfizer”) about its decision to terminate the Research Collaboration and License Agreement, which the two companies entered in December 2011. Following the wind-down of this agreement, there will be no active collaboration agreements between …

Karo Pharma acquires product portfolio from LEO Pharma

Karo Pharma acquires a focused intimate care and dermatology product portfolio from the Danish pharmaceutical company LEO Pharma for 90 MEUR. The turnover of the acquired portfolio is estimated to 35 MEUR for the full year of 2019. Approximately 2/3 of the turnover comes from European markets. The p…

Åsa Riisberg leaves the Board of Directors of Karo Pharma at her own request

Åsa Riisberg has notified the Board of Directors of Karo Pharma that she, due to a number of time-consuming commitments, wishes to leave her position as member of the Board of Directors. She resigned from the Board of Directors 10 December 2019. Pursuant to the Articles of Association of Karo Pharma…
Show more

Karo Pharma Frequently Asked Questions

  • When was Karo Pharma founded?

    Karo Pharma was founded in 1987.

  • Who are Karo Pharma key executives?

    Karo Pharma's key executives are Christoffer Lorenzen, Jon Johnsson and Magnus Nylén.

  • How many employees does Karo Pharma have?

    Karo Pharma has 193 employees.

  • Who are Karo Pharma competitors?

    Competitors of Karo Pharma include Enzymatica, Octagon Therapeutics and Lead Pharma.

  • Where is Karo Pharma headquarters?

    Karo Pharma headquarters is located at Klara Norra kyrkogata 33, Stockholm.

  • Where are Karo Pharma offices?

    Karo Pharma has an office in Stockholm.

  • How many offices does Karo Pharma have?

    Karo Pharma has 2 offices.